BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

933 related articles for article (PubMed ID: 27110810)

  • 21. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
    Asahi-Ozaki Y; Itamura S; Ichinohe T; Strong P; Tamura S; Takahashi H; Sawa H; Moriyama M; Tashiro M; Sata T; Kurata T; Hasegawa H
    Microbes Infect; 2006 Oct; 8(12-13):2706-14. PubMed ID: 16968669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.
    Zheng D; Chen S; Qu D; Chen J; Wang F; Zhang R; Chen Z
    Vaccine; 2016 Dec; 34(51):6464-6471. PubMed ID: 27866773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-protection against influenza B type virus infection by intranasal inoculation of the HA vaccines combined with cholera toxin B subunit.
    Kikuta K; Hirabayashi Y; Nagamine T; Aizawa C; Ueno Y; Oya A; Kurata T; Tamura S
    Vaccine; 1990 Dec; 8(6):595-9. PubMed ID: 1965078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.
    Liu WC; Liu YY; Chen TH; Liu CC; Jan JT; Wu SC
    Antiviral Res; 2016 Sep; 133():110-8. PubMed ID: 27491439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucosal vaccination of conserved sM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes.
    Chowdhury MYE; Kim TH; Uddin MB; Kim JH; Hewawaduge CY; Ferdowshi Z; Sung MH; Kim CJ; Lee JS
    Vet Microbiol; 2017 Mar; 201():240-251. PubMed ID: 28284616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple Neuraminidase Containing Influenza Virus-like Particle Vaccines Protect Mice from Avian and Human Influenza Virus Infection.
    Kang HJ; Chu KB; Yoon KW; Eom GD; Mao J; Kim MJ; Lee SH; Moon EK; Quan FS
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35216022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine.
    Tamura SI; Samegai Y; Kurata H; Kikuta K; Nagamine T; Aizawa C; Kurata T
    Vaccine; 1989 Jun; 7(3):257-62. PubMed ID: 2781859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
    Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
    Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses.
    Mohan T; Kim J; Berman Z; Wang S; Compans RW; Wang BZ
    J Control Release; 2016 Jul; 233():208-19. PubMed ID: 27178810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
    Wang D; Christopher ME; Nagata LP; Zabielski MA; Li H; Wong JP; Samuel J
    J Clin Virol; 2004 Dec; 31 Suppl 1():S99-106. PubMed ID: 15567101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.
    Dong W; Bhide Y; Sicca F; Meijerhof T; Guilfoyle K; Engelhardt OG; Boon L; de Haan CAM; Carnell G; Temperton N; de Vries-Idema J; Kelvin D; Huckriede A
    Front Immunol; 2018; 9():2312. PubMed ID: 30356772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit.
    Tamura S; Kurata H; Funato H; Nagamine T; Aizawa C; Kurata T
    Vaccine; 1989 Aug; 7(4):314-20. PubMed ID: 2815967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influenza virus-like particles composed of conserved influenza proteins and GPI-anchored CCL28/GM-CSF fusion proteins enhance protective immunity against homologous and heterologous viruses.
    Liu J; Ren Z; Wang H; Zhao Y; Wilker PR; Yu Z; Sun W; Wang T; Feng N; Li Y; Wang H; Ji X; Li N; Yang S; He H; Qin C; Gao Y; Xia X
    Int Immunopharmacol; 2018 Oct; 63():119-128. PubMed ID: 30081250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit.
    Tamura S; Samegai Y; Kurata H; Nagamine T; Aizawa C; Kurata T
    Vaccine; 1988 Oct; 6(5):409-13. PubMed ID: 2848377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses.
    Yang JR; Chen CY; Kuo CY; Cheng CY; Lee MS; Cheng MC; Yang YC; Wu CY; Wu HS; Liu MT; Hsiao PW
    Antiviral Res; 2016 Feb; 126():8-17. PubMed ID: 26593980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein.
    Guo L; Zheng M; Ding Y; Li D; Yang Z; Wang H; Chen Q; Sui Z; Fang F; Chen Z
    Arch Virol; 2010 Nov; 155(11):1765-75. PubMed ID: 20652335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin).
    Matsuo K; Yoshikawa T; Asanuma H; Iwasaki T; Hagiwara Y; Chen Z; Kadowaki SE; Tsujimoto H; Kurata T; Tamura SI
    Vaccine; 2000 Jun; 18(24):2713-22. PubMed ID: 10781859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response.
    Hodgins B; Yam KK; Winter K; Pillet S; Landry N; Ward BJ
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).
    Matassov D; Cupo A; Galarza JM
    Viral Immunol; 2007 Sep; 20(3):441-52. PubMed ID: 17931114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles.
    Ramirez A; Morris S; Maucourant S; D'Ascanio I; Crescente V; Lu IN; Farinelle S; Muller CP; Whelan M; Rosenberg W
    Vaccine; 2018 Feb; 36(6):873-880. PubMed ID: 29306508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.